Zai Lab Limited filings document the SEC reporting record for its American depositary shares and the governance and financing disclosures of a Cayman Islands biopharmaceutical issuer. Form 8-K reports furnish quarterly and annual operating results, financial-condition updates and clinical or regulatory corporate updates tied to its oncology, immunology, neuroscience and infectious disease programs.
The filing record also includes proxy materials covering annual meeting matters, board governance, executive compensation and equity awards. Material-event reports describe capital-structure and liquidity matters, including working-capital credit arrangements, guarantees for Zai Lab Shanghai and related covenant disclosures, while ADR disclosures distinguish the SEC-registered depositary shares from ordinary shares listed in Hong Kong.
Zai Lab Ltd Chief Legal Officer Edmondson Frazor Titus III reported an open-market sale of 3,517 American Depositary Shares (ADS) on May 14, 2026 at a price of $20.19 per ADS. Each ADS represents ten Ordinary Shares of Zai Lab.
Following the transaction, he directly holds 19,849 ADS. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
Zai Lab Ltd Chairperson and CEO Du Ying reported option exercises and share sales in American Depositary Shares (ADSs). On May 13–14, 2026, Du Ying exercised stock options to acquire 100,000 ADSs at a price of $1.74 per ADS equivalent, then sold 100,000 ADSs in open-market transactions at weighted average prices of $19.4432, $20.2223, and $20.0915 per ADS.
After these transactions, Du Ying directly holds 1,122,626 ADSs and 361,092 stock options outstanding. All trades were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 11, 2025, indicating the timing was set in advance rather than decided opportunistically.
ZLAB reported proposed sales of American Depositary Shares by an insider, listing multiple transactions and dates. The notice itemizes repeated proposed dispositions of 50,000 ADS lots on several dates and smaller dispositions (for example, 1,067 ADS on 03/11/2026). Transaction entries show trade dates, share counts and gross proceeds for each line item.
ZLAB insider reported proposed and completed sales of American Depositary Shares (ADS). The filing lists multiple ADS dispositions by Ying Du, including 50,000-share transactions dated 03/04/2026, 03/05/2026, 03/06/2026, 03/09/2026 and 05/13/2026. Several other smaller ADS sales are shown in March and April 2026.
ZLAB insider notice of proposed resale activity: multiple American Depositary Shares were listed as sold or to be sold under restricted stock vesting and compensation arrangements. The excerpt lists specific vesting entries of 550 ADS (04/03/2025) and 2,967 ADS (08/17/2025), and several sales by an individual during March–April 2026.
Issuer reported Form 144 notice to sell 50,000 American Depositary Shares. The filing lists an option granted on 08/25/2016 and a planned sale of 50,000 ADS on 05/13/2026 for $960,000.00. The filing also reports multiple ADS dispositions by Ying Du between 03/04/2026 and 04/06/2026, including several blocks of 50,000 ADS and smaller sales that together appear in the reported transaction history.
Zai Lab Limited reported first-quarter 2026 revenue of $99.6 million, with net product revenue of $95.6 million, down 10% year over year, and a net loss of $51.0 million (loss of $0.05 per ordinary share).
Sales declined mainly because ZEJULA revenue fell 39% to $30.0 million after volume-based procurement for generic olaparib, and VYVGART revenue softened following a pricing adjustment tied to NRDL renewal. These pressures were partly offset by strong growth from XACDURO, whose revenue rose to $8.6 million, and continued gains from NUZYRA and OPTUNE.
The company increased research and development spending to $65.6 million, driven by higher clinical trial and licensing costs, while selling, general, and administrative expenses rose modestly to $65.1 million. Zai Lab ended the quarter with $761.3 million in cash, cash equivalents, current restricted cash, and short-term investments and $213.8 million in short-term debt, supporting ongoing late-stage programs and new collaborations highlighted in oncology and immunology.
Zai Lab Limited reported first-quarter 2026 total revenue of $99.6 million, down 6% year over year, as weaker oncology sales offset growth in newer products. Net product revenue was $95.6 million, a 10% decline, mainly from lower ZEJULA and VYVGART sales.
ZEJULA revenue fell to $30.0 million from $49.5 million due to volume-based procurement for a competing generic, while VYVGART slipped to $17.6 million after a pricing adjustment tied to NRDL renewal. XACDURO and NUZYRA grew to $8.6 million and $16.3 million, respectively.
Research and development expenses rose to $65.6 million and SG&A to $65.1 million, leading to a GAAP operating loss of $69.4 million and net loss of $51.0 million, or $0.05 per ordinary share. Zai Lab ended March 31, 2026 with $761.3 million in cash, equivalents, short-term investments, and current restricted cash.
The company highlighted standout intracranial response data for its DLL3-targeting ADC zocilurtatug pelitecan in small cell lung cancer and epNECs, new collaborations with Amgen and Boehringer Ingelheim, advancing atopic dermatitis candidate ZL-1503, and positive Phase 3 data from partners’ programs povetacicept in IgA nephropathy and elegrobart in thyroid eye disease.
Zai Lab Limited is calling its 2026 Annual General Meeting for June 17, 2026, in Shanghai with a concurrent virtual option. Shareholders will vote on re-electing nine directors, appointing KPMG LLP and KPMG as 2026 auditors, and giving the Board authority to set auditor fees.
They will also cast an advisory “say-on-pay” vote on named executive officer compensation. Two key capital authorizations are proposed: a general mandate allowing the Board to issue or resell up to 10% of issued ordinary shares and a separate mandate to repurchase up to 10% of issued ordinary shares, each effective until the 2027 meeting.